- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods -- Project Slated for Completion Coincident with...
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company...
STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in...
Management Adding Critical Leadership Roles to Support Growth of Recently Launched CDMO Business UnitVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp....
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products,...
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused...
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to...
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided...
SALT LAKE CITY, UT / ACCESSWIRE / March 12, 2024 / CenExel, a leading clinical research site network with 18...
The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the...
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
Represents a $0.15 Per Share Increase Over 2023 Special DividendNEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc....
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data...
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced...
Conference call to begin at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),...
HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology...
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in...